Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Greater reductions in C-reacti...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
Bibliographic Details
Main Authors:
Haffner, S
,
Kahn, SE
,
Zinman, B
,
Holman, R
,
Viberti, G
,
Herman, W
,
Lachin, J
,
Kravitz, BG
,
Heise, M
Format:
Conference item
Published:
2007
Holdings
Description
Similar Items
Staff View
Similar Items
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
by: Kahn, SE, et al.
Published: (2010)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
by: Kahn, SE, et al.
Published: (2006)
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
by: Lachin, J, et al.
Published: (2011)
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
by: Kahn, SE, et al.
Published: (2011)
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
by: Zinman, B, et al.
Published: (2010)